Common (>10%): Mild oily skin, minor acne (face, back), modest hematocrit elevation, modest LDL rise / HDL drop, injection-site mild soreness (oil-based IM).

Less common (1-10%): Increased aggression / mood shift (less than testosterone or trenbolone), libido changes (paradoxically can decrease in methenolone-only cycles due to lack of aromatization → low estradiol), mild hair-loss acceleration in genetically susceptible users, transient liver-enzyme elevation (oral acetate, mild — substantially less than 17αα orals).

Rare-serious (<1%): Peliosis hepatis (vascular hepatic complication, more associated with 17αα orals but methenolone acetate fatal case documented — Solans-Domenech 1993, PMID 8334198), prolonged hypogonadism after withdrawal (Rasmussen 2016), polycythemia requiring phlebotomy (less likely than with boldenone or testosterone), severe lipid disturbance, blood pressure elevation.

Theoretical concerns / class-wide:

• Cardiovascular long-term risk. AAS-class effect — Pope HG Jr et al. 2014 (Endocrine Reviews 35:341) and Kanayama / Pope long-term cohort work documents accelerated cardiomyopathy, atherosclerosis, and dysrhythmia in chronic AAS users. Methenolone is on the milder end of this profile but not exempt.
• HPG-axis permanent shutdown. Real risk in young / chronic users. Methenolone's "milder suppression" claim is dose-dependent — at clinical doses suppression is modest, at physique doses it's substantial.
• Female virilization permanence. Voice changes and clitoral enlargement often do not reverse on discontinuation. STOP IMMEDIATELY at first virilization sign.
• Counterfeit substitution. The most-likely "side effect" the average user actually encounters is "this isn't methenolone." Substituted compound (testosterone, nandrolone, boldenone) carries its OWN side-effect profile — typically MORE side effects than expected because user dosed for "mild methenolone" but actually injected a stronger AAS.

Specific watch periods: Week 3-4 lab check (hematocrit, lipids, LFTs, total T trend if monitoring suppression); week 6-8 mid-cycle check; post-cycle week 4 (HPG recovery onset); post-cycle week 12 (full HPG recovery should be present in healthy first-cycle users).

WADA / commission detection windows: Methenolone enanthate detectable in urine ~5-10 weeks post-cycle for routine GC-MS; >30 days for long-term sulfate metabolites via current LC-HRMS / GC-HRMS methods (Albertsdóttir 2020, PMID 32386339). Acetate slightly shorter (4-6 weeks routine, 20-30 days for long-term metabolites). For tested MMA: assume methenolone is detectable for at minimum 6 weeks post-cycle and likely much longer with current testing technology.